{"id":26145,"date":"2024-04-08T20:53:00","date_gmt":"2024-04-08T20:53:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4382330_CN82330_0"},"modified":"2024-04-08T20:53:00","modified_gmt":"2024-04-08T20:53:00","slug":"oral-report-the-positive-interim-analysis-results-from-the-phase-iii-clinical-study-of-akesos-cadonilimab-pd-1-ctla-4-bsab-plus-chemotherapy-as-first-line-treatment-for-advanced-gastric-cancer-pr","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=26145","title":{"rendered":"Oral report | The positive interim analysis results from the Phase III clinical study of Akeso’s Cadonilimab (PD-1\/CTLA-4 BsAb) plus chemotherapy as first-line treatment for advanced gastric cancer presented at 2024 AACR"},"content":{"rendered":"\n

SAN DIEGO<\/span>, April 9, 2024 \/PRNewswire\/ — Akeso, Inc. (9926.HK) today announced that the positive interim analysis results from <\/b>Phase III clinical study of Cadonilimab (PD-1\/CTLA-4 BsAb) <\/b>combined with XELOX (capecitabine plus oxaliplatin) as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma (AK104-302\/COMPASSION-15) were released presented in the form of oral presentation at the 2024 American Association for Cancer Research (AACR).<\/span><\/p>\n

The COMPASSION-15 is the world’s first Phase III clinical study of PD-1\/CTLA-4 bispecific antibody combined with chemotherapy as first-line treatment for gastric cancer. In COMPASSION-15 , the proportions of patients with PD-L1 CPS <5 (PD-L1 low expression) and PD-L1 CPS <1 (PD-L1 negative)  in the intention-to-treat population (ITT) were 49.8% and 23%, respectively, which is much higher than that in previous Phase III clinical studies of immune checkpoint inhibitors combined regimens for first-line gastric cancer globally. Previous studies have shown that patients with PD-L1 low expression\/negative generally have poor efficacy with immunotherapy.<\/p>\n

As of the interim analysis, with a median follow-up of 18.7 months, the proportions of subsequent systemic treatment in the Cadonilimab combination therapy group and chemotherapy group were 36.4% vs 50.5%, respectively, and the proportions of subsequent treatment using PD-1\/PD-L1 inhibitors were 11.1% vs 21.6%, respectively.<\/p>\n

The results showed that regardless of PD-L1 expression, Cadonilimab combination therapy significantly prolonged patients’ overall survival benefits and reduced the risk of death compared to chemotherapy, with outstanding benefits in objective response and long-term survival. Even for the patients with low PD-L1 expression, it also showed excellent efficacy, which is expected to compensate for the limited efficacy of PD-1 monotherapy for first-line treatment of low PD-L1  expression gastric cancer, providing a more comprehensive and efficient immunotherapy regimen for advanced gastric cancer patients.<\/p>\n

Cadonilimab plus chemo therapy significantly prolonged survival benefits as first-line treatment for advanced gastric cancer, comprehensively reducing the risk of progression\/death.<\/p>\n

l  In the ITT population\uff0cthe median overall survival (mOS)  was longer in the combination therapy group versus the chemotherapy group (HR=0.62 \uff0cmOS 15.0mo vs 10.8 mo; P<0.001)\uff0cwith a 39% prolongation of mOS and a 38% reduction in the risk of death\uff1b<\/p>\n